These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 28004413)

  • 21. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
    Ezekowitz MD; Nagarakanti R; Noack H; Brueckmann M; Litherland C; Jacobs M; Clemens A; Reilly PA; Connolly SJ; Yusuf S; Wallentin L
    Circulation; 2016 Aug; 134(8):589-98. PubMed ID: 27496855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease: an update.
    Ha AC; Verma A; Verma S
    Curr Opin Cardiol; 2017 Mar; 32(2):174-180. PubMed ID: 27861189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; de Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B
    Thromb Haemost; 2017 Dec; 117(12):2215-2236. PubMed ID: 29212110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation in Atrial Fibrillation Associated with Mitral Stenosis.
    da Silva RMFL
    Cardiovasc Hematol Agents Med Chem; 2022; 20(3):172-174. PubMed ID: 35319395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease.
    Renda G; Ricci F; Giugliano RP; De Caterina R
    J Am Coll Cardiol; 2017 Mar; 69(11):1363-1371. PubMed ID: 28302287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations.
    Stacy ZA; Richter SK
    Ther Adv Cardiovasc Dis; 2018 Sep; 12(9):247-262. PubMed ID: 30081727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.
    Malik AH; Yandrapalli S; Aronow WS; Panza JA; Cooper HA
    Heart; 2019 Sep; 105(18):1432-1436. PubMed ID: 31203254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis.
    Banerjee A; Allan V; Denaxas S; Shah A; Kotecha D; Lambiase PD; Joseph J; Lund LH; Hemingway H
    Europace; 2019 Dec; 21(12):1776-1784. PubMed ID: 31408153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the New Oral Anticoagulants and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Systematic Review and Meta-Analysis.
    de Souza Lima Bitar Y; Neto MG; Filho JAL; Pereira LV; Travassos KSO; Akrami KM; Roever L; Duraes AR
    Drugs R D; 2019 Jun; 19(2):117-126. PubMed ID: 31055767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension-a Systematic Review.
    Brokmeier H; Kido K
    Ann Pharmacother; 2021 Aug; 55(8):995-1009. PubMed ID: 33148014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and Prognosis of Patients With Nonvalvular Atrial Fibrillation and Significant Valvular Heart Disease Referred for Electrical Cardioversion.
    Vo NM; Leung M; van Rosendael PJ; Goedemans L; van Wijngaarden SE; Prihadi EA; van der Bijl P; Ajmone Marsan N; Delgado V; Bax JJ
    Am J Cardiol; 2020 Aug; 128():84-91. PubMed ID: 32650929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct oral anticoagulation in atrial fibrillation and heart valve surgery-a meta-analysis and systematic review.
    Gerfer S; Djordjevic I; Eghbalzadeh K; Mader N; Wahlers T; Kuhn E
    Ther Adv Cardiovasc Dis; 2022; 16():17539447221093963. PubMed ID: 35481366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis.
    Caldeira D; David C; Costa J; Ferreira JJ; Pinto FJ
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):111-118. PubMed ID: 28950374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease : A Population-Based Study.
    Dawwas GK; Cuker A; Barnes GD; Lewis JD; Hennessy S
    Ann Intern Med; 2022 Nov; 175(11):1506-1514. PubMed ID: 36252244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience.
    Russo V; Attena E; Mazzone C; Esposito F; Parisi V; Bancone C; Rago A; Nigro G; Sangiuolo R; D' Onofrio A
    Semin Thromb Hemost; 2018 Jun; 44(4):364-369. PubMed ID: 29304513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
    Cope S; Clemens A; Hammès F; Noack H; Jansen JP
    Value Health; 2015 Mar; 18(2):234-49. PubMed ID: 25773559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.